Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20

BACKGROUND: Rituximab is used in the treatment of CD20(+) B cell lymphomas and other B cell lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations with other drugs such as statins that inhibit cholesterol synthesis and show promising antilymphoma effects. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Winiarska, Magdalena, Bil, Jacek, Wilczek, Ewa, Wilczynski, Grzegorz M, Lekka, Malgorzata, Engelberts, Patrick J, Mackus, Wendy J. M, Gorska, Elzbieta, Bojarski, Lukasz, Stoklosa, Tomasz, Nowis, Dominika, Kurzaj, Zuzanna, Makowski, Marcin, Glodkowska, Eliza, Issat, Tadeusz, Mrowka, Piotr, Lasek, Witold, Dabrowska-Iwanicka, Anna, Basak, Grzegorz W, Wasik, Maria, Warzocha, Krzysztof, Sinski, Maciej, Gaciong, Zbigniew, Jakobisiak, Marek, Parren, Paul W. H. I, Golab, Jakub
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270297/
https://www.ncbi.nlm.nih.gov/pubmed/18366248
http://dx.doi.org/10.1371/journal.pmed.0050064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270297/
https://www.ncbi.nlm.nih.gov/pubmed/18366248
http://dx.doi.org/10.1371/journal.pmed.0050064

Ejemplares similares